Skip to main content

Advertisement

Table 1 Patient characteristics with and without metabolic syndrome

From: Association of HIV-infection, antiretroviral treatment and metabolic syndrome with large artery stiffness: a cross-sectional study

  No Metabolic Syndrome Metabolic Syndrome
(N = 113) (N = 38)
Variable Controls (n = 39) HIV-1 untreated (n = 32) HIV-1 cART (n = 42) Controls (n = 10) HIV-1 untreated (n = 16) HIV-1 cART (n = 12)
Age, year 45 ± 3 44 ± 6 46 ± 5 45 ± 4 47 ± 5 47 ± 4
Men, % 69 28 29 50 13 25
Body mass, kg 67.8 ± 11.8 64.7 ± 9.7 58.5 ± 11.5a 81.1 ± 10.6c 71.2 ± 12.7c 75.0 ± 15.6c
BMI, kg/m2 24.8 ± 4.2 24.3 ± 3.9 22.5 ± 4.1a 30.4 ± 4.6c 26.7 ± 3.2c 28.9 ± 4.1c
Body fat, % 32 ± 9 35 ± 7 33 ± 8 38 ± 5c 40 ± 4c 40 ± 4c
Waist circumference, cm 85 ± 10 81 ± 7 81 ± 11 95 ± 8c 92 ± 9c 98 ± 6c
Systolic BP, mmHg 124 ± 12 126 ± 9 120 ± 11 135 ± 7c 135 ± 13c 131 ± 18c
Diastolic BP, mmHg 74 ± 7 76 ± 5 74 ± 8 79 ± 3c 79 ± 6 79 ± 6c
LDL-cholesterol, mmol/l 2.9 ± 0.9 2.5 ± 0.8 2.7 ± 1.0 3.1 ± 0.7 2.8 ± 1.1 3.2 ± 0.9
HDL-cholesterol, mmol/l 1.2 ± 0.4 1.1 ± 0.5 1.4 ± 0.6b 1.0 ± 0.6 0.8 ± 0.3 1.1 ± 0.3
Triglycerides, mmol/l 1.1 ± 0.7 1.0 ± 0.4 1.4 ± 1.1 2.3 ± 1.5c 1.3 ± 0.6 2.0 ± 1.2
Glucose, mmol/l 4.7 ± 0.6 4.5 ± 0.7 4.8 ± 0.6 5.0 ± 0.7 4.8 ± 0.9 4.7 ± 0.7
CD4 at enrollment, cells/μL 665 ± 142 289 ± 46b 666 ± 120 302 ± 41b
CD4 (most recent), cells/μL 493 ± 250d 494 ± 229d 430 ± 255d 480 ± 189d
Months of HIV-1 infection, median 21.5 29.3b 20.6 39.8b
Months cART, median 24.0 30.9
  1. Values are means ± SD unless otherwise noted. BMI body mass index, BP blood pressure, LDL low-density lipoprotein, HDL high-density lipoprotein, cART combined antiretroviral therapy, aP < 0.05 vs. within-group controls, bP < 0.05 vs. within-group HIV-1 untreated patients, cP < 0.05 vs. corresponding group without metabolic syndrome, d P < 0.01 vs. within-group CD4 at enrollment